Abstract
A phase II trial of recombinant human gamma-interferon in the treatment of unresectable primary hepatocellular carcinoma is reported. The trial was terminated prematurely after recruitment of only 7 patients because of unacceptable toxicity, predominantly renal. There was no evidence of response in any of the 7 patients but some evidence that disease progression was more rapid during the treatment period.
Original language | English |
---|---|
Pages (from-to) | 826-829 |
Number of pages | 4 |
Journal | Journal of the Royal Society of Medicine |
Volume | 78 |
Issue number | 10 |
DOIs | |
Publication status | Published - Oct 1985 |
Keywords
- Adult
- Carcinoma, Hepatocellular
- Drug Evaluation
- Female
- Humans
- Interferon-gamma
- Liver Neoplasms
- Male
- Middle Aged
- Time Factors
- alpha-Fetoproteins